AMGN vs NVO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Amgen presents a complex profile with a stable Piotroski F-Score of 6/9, indicating reasonable operational health, yet it is burdened by an extremely high Debt/Equity ratio of 6.40. While the current price of $338.02 sits comfortably below the growth-based intrinsic value of $419.79, the stock is facing significant headwinds from bearish insider sentiment and a 0/100 technical trend. Strong historical earnings beats are currently offset by a sharp recent decline in YoY EPS growth (-53.9%). The outlook remains neutral as the market weighs strong profitability and a reasonable forward P/E against aggressive leverage and insider selling.
NVO presents a dichotomy between elite profitability and deteriorating growth. The Piotroski F-Score of 4/9 indicates stable but non-improving financial health, while the current price of $42.22 trades at a significant premium to both the Graham Number ($23.58) and Intrinsic Value ($25.27). Despite an exceptional ROE of 60.7% and strong margins, the company is facing negative YoY revenue (-7.6%) and earnings growth (-4.7%), resulting in a high PEG ratio of 4.53. The outlook is tempered by a bearish technical trend and liquidity concerns, though supported by a strong dividend profile and analyst 'Buy' ratings.
Compare Another Pair
Related Comparisons
AMGN vs NVO: Head-to-Head Comparison
This page compares Amgen Inc. (AMGN) and Novo Nordisk A/S (NVO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.